Smart-watch-programmed green-light-operated percutaneous control of therapeutic transgenes.
Maysam MansouriMarie-Didiée HussherrTobias StrittmatterPeter BuchmannShuai XueGieri CamenischMartin FusseneggerPublished in: Nature communications (2021)
Wearable smart electronic devices, such as smart watches, are generally equipped with green-light-emitting diodes, which are used for photoplethysmography to monitor a panoply of physical health parameters. Here, we present a traceless, green-light-operated, smart-watch-controlled mammalian gene switch (Glow Control), composed of an engineered membrane-tethered green-light-sensitive cobalamin-binding domain of Thermus thermophilus (TtCBD) CarH protein in combination with a synthetic cytosolic TtCBD-transactivator fusion protein, which manage translocation of TtCBD-transactivator into the nucleus to trigger expression of transgenes upon illumination. We show that Apple-Watch-programmed percutaneous remote control of implanted Glow-controlled engineered human cells can effectively treat experimental type-2 diabetes by producing and releasing human glucagon-like peptide-1 on demand. Directly interfacing wearable smart electronic devices with therapeutic gene expression will advance next-generation personalized therapies by linking biopharmaceutical interventions to the internet of things.
Keyphrases
- gene expression
- type diabetes
- heart rate
- physical activity
- endothelial cells
- healthcare
- mental health
- minimally invasive
- binding protein
- public health
- poor prognosis
- dna methylation
- health information
- cardiovascular disease
- radiofrequency ablation
- ultrasound guided
- genome wide
- adipose tissue
- insulin resistance
- small molecule
- blood pressure
- skeletal muscle
- risk assessment
- dna binding